GlobeNewsWire
22 Jun 2026, 20:43 UTC · 2h ago
MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
GlobeNewsWire
22 Jun 2026, 20:43 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
MacroGenics will receive a $24.5 million regulatory milestone payment from Sanofi following the FDA's accelerated approval of TZIELD for children aged 8 to 17 with stage 3 type 1 diabetes. — Immediate non-dilutive cash inflow provides a direct boost to the balance sheet and validates the commercial utility of the drug.
+0.60The FDA approval expands TZIELD's indication to include children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes. — Expansion of the target patient population increases the total addressable market and future royalty potential.
+0.50MacroGenics remains eligible for up to $305 million in additional milestone payments and retains rights to single-digit royalties on global net sales above a specified threshold. — Establishes significant long-term upside potential, though payments are contingent on future milestones.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is receiving a $24.5 million milestone payment and expanding the therapeutic potential of TZIELD via FDA approval.
Sanofi received FDA accelerated approval for TZIELD to treat children with stage 3 type 1 diabetes, expanding its market reach.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
1d ago
